Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Euro-Med Laboratories Philippines Cash Conversion Cycle Related Terms
Euro-Med Laboratories Philippines Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHS:EURO vs ZTS, UTHR, VTRS: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euro-Med Laboratories Philippines (PHS:EURO) has a Cash Conversion Cycle of 211.75 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Euro-Med Laboratories Philippines and its competitors.
Is Euro-Med Laboratories Philippines' Cash Conversion Cycle too high?
Euro-Med Laboratories Philippines' current Cash Conversion Cycle is 211.75. The Drug Manufacturers industry median Cash Conversion Cycle is 145.82. Euro-Med Laboratories Philippines' value of 211.75 is 45.2% above this industry median. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' Cash Conversion Cycle compare to ZTS and UTHR?
Euro-Med Laboratories Philippines' Cash Conversion Cycle of 211.75 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. Euro-Med Laboratories Philippines' value of 211.75 is 45.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current Cash Conversion Cycle of 211.75 is 45.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Euro-Med Laboratories Philippines and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current Cash Conversion Cycle is 211.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.02, compared to a current price of ₱1.10 — trading 7.8% above its estimated fair value. The current Cash Conversion Cycle is 211.75 and 45.2% above the Drug Manufacturers industry median of 145.82. Euro-Med Laboratories Philippines' overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current Cash Conversion Cycle is 211.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be overvalued.
The current stock price of ₱1.10 is trading 7.8% above its estimated GF Value™ of ₱1.02.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
Cash Conversion Cycle: 211.75
GF Value™: ₱1.02 vs. price of ₱1.10 (7.8% above fair value)
Industry Position: 45.2% above the Drug Manufacturers median
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Business Description
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
82GF Score
Get the complete analysis for PHS:EURO
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
